Coverage
-
January 16, 2026
Pomerantz LLP will lead a proposed class of investors accusing biopharmaceutical company Biohaven Ltd. of overstating the odds that two of its product candidates would receive regulatory approval, a Connecticut judge said Friday.
1 other articles on this case.
View all »